News &
Media
-
Neurotech Releases ASD Medical Cannabis Study Results
View More: Neurotech Releases ASD Medical Cannabis Study ResultsAustralia’s Neurotech International Limited (ASX: NTI) has announced what it says are successful outcomes of its medical cannabis formulation on key behavioural issues impacting kids with autism.
-
Neurotech International (ASX:NTI) Webinar – Breakthrough results with NTI164 in paediatric ASD
View More: Neurotech International (ASX:NTI) Webinar – Breakthrough results with NTI164 in paediatric ASD -
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View More: Neurotech study says cannabis could be key to helping kids on the spectrum reach potentialNeurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
-
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View More: Neurotech study says cannabis could be key to helping kids on the spectrum reach potentialNeurotech has released promising results from a world-first study of a medicinal cannabis product which could be a game changer in treating children with autism.
-
Neurotech study finds children with autism benefit from cannabis product
View More: Neurotech study finds children with autism benefit from cannabis productNeurotech International (ASX:NTI) has today announced its patent NTI164 product has been proven to reduce ASD symptoms in children and teenagers.
-
Neurotech International announces breakthrough results from autism study
View More: Neurotech International announces breakthrough results from autism studyNeurotech International has announced breakthrough results from a clinical trial of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis study
View More: Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis studyNeurotech International (NTI) has reported that 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with autism spectrum disorder (ASD).
-
Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
View More: Neurotech reports clinical trial results for world first Autism Spectrum Disorder drugThe cannabinoid based drug, licensed from Dolve Cann Global is the world’s first full-spectrum medicinal cannabis product (with less than 0.3% THC).
-
Neurotech tackles the anguish of autism with low-THC cannabis treatment
View More: Neurotech tackles the anguish of autism with low-THC cannabis treatmentA medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.